-
1.发明申请Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity 审中-公开免疫刺激核酸包装颗粒治疗超敏反应公开(公告)号：US20070184068A1
公开(公告)日：2007-08-09
申请号：US11638664
申请日：2006-12-14
申请人： Wolfgang Renner , Martin Bachmann , Indulis Cielens , Conrad Coester , Klaus Dietmeier , Sebastian Fuchs , Vania Manolova , Patrik Maurer , Paul Pumpens , Regina Renhofa , Alain Tissot , Yu Zou
发明人： Wolfgang Renner , Martin Bachmann , Indulis Cielens , Conrad Coester , Klaus Dietmeier , Sebastian Fuchs , Vania Manolova , Patrik Maurer , Paul Pumpens , Regina Renhofa , Alain Tissot , Yu Zou
CPC分类号： A61K39/12 , A61K39/39 , A61K47/6901 , A61K47/6931 , A61K49/0004 , A61K49/0093 , A61K49/0097 , A61K2039/5258 , A61K2039/55555 , A61K2039/55561 , B82Y5/00 , C12N2795/18123
摘要： The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
摘要翻译： 本申请涉及治疗超敏反应的组合物和方法，其中组合物包含用免疫刺激核酸包装的颗粒。 本发明的组合物特别可用于治疗特应性湿疹，哮喘和IgE介导的过敏（I型过敏），特别是花粉过敏和房屋尘埃过敏。
-
公开(公告)号：US20070128219A1
公开(公告)日：2007-06-07
申请号：US11601687
申请日：2006-11-20
申请人： Martin Bachmann , Alain Tissot , Paul Pumpens , Indulis Cielens , Regina Renhofa
发明人： Martin Bachmann , Alain Tissot , Paul Pumpens , Indulis Cielens , Regina Renhofa
IPC分类号： A61K39/395 , A61K39/12
CPC分类号： C12N7/00 , A61K39/00 , A61K39/0005 , A61K39/35 , A61K2039/5256 , A61K2039/5258 , A61K2039/6075 , C07K14/005 , C07K14/5409 , C07K16/24 , C07K16/40 , C07K2317/34 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C12N2795/18122 , C12N2795/18123 , Y02A50/412
摘要： The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.
摘要翻译： 本发明提供包含AP205病毒样颗粒（VLP）和抗原的组合物。 本发明还提供了一种制备与AP205 VLP结合的抗原或抗原决定簇的方法。 与抗原结合的AP205 VLP可用于产生用于诱导免疫应答的组合物，其可用于预防或治疗疾病，病症或病症，包括感染性疾病，过敏，癌症，药物成瘾，中毒，并有效诱导自身特异性 免疫应答，特别是抗体应答。
-
公开(公告)号：US07494656B2
公开(公告)日：2009-02-24
申请号：US11601687
申请日：2006-11-20
申请人： Martin Bachmann , Alain Tissot , Paul Pumpens , Indulis Cielens , Regina Renhofa
发明人： Martin Bachmann , Alain Tissot , Paul Pumpens , Indulis Cielens , Regina Renhofa
IPC分类号： A61K39/145 , A61K39/385 , C12N7/00 , C12N15/09
CPC分类号： C12N7/00 , A61K39/00 , A61K39/0005 , A61K39/35 , A61K2039/5256 , A61K2039/5258 , A61K2039/6075 , C07K14/005 , C07K14/5409 , C07K16/24 , C07K16/40 , C07K2317/34 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C12N2795/18122 , C12N2795/18123 , Y02A50/412
摘要： The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.
摘要翻译： 本发明提供包含AP205病毒样颗粒（VLP）和抗原的组合物。 本发明还提供了一种制备与AP205 VLP结合的抗原或抗原决定簇的方法。 与抗原结合的AP205 VLP可用于产生用于诱导免疫应答的组合物，其可用于预防或治疗疾病，病症或病症，包括感染性疾病，过敏，癌症，药物成瘾，中毒，并有效诱导自身特异性 免疫应答，特别是抗体应答。
-
公开(公告)号：US20060251677A1
公开(公告)日：2006-11-09
申请号：US10550518
申请日：2004-03-25
申请人： Martin Bachmann , Andreas Cornelius , Vania Manolova , Patrik Maurer , Edwin Meijerink , Karl Proba , Katrin Schwarz
发明人： Martin Bachmann , Andreas Cornelius , Vania Manolova , Patrik Maurer , Edwin Meijerink , Karl Proba , Katrin Schwarz
CPC分类号： C12N15/117 , A61K39/0011 , A61K39/12 , A61K39/21 , A61K39/39 , A61K2039/5258 , A61K2039/55561 , A61K2039/6075 , C07K14/005 , C07K14/4748 , C07K2319/00 , C12N2310/18 , C12N2710/20022 , C12N2730/10122 , C12N2730/10123 , C12N2730/10134 , C12N2740/16222 , C12N2740/16234 , C12N2760/10022 , C12N2760/10034 , C12N2795/18122 , C12N2795/18123 , Y02A50/467
摘要： The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
-
公开(公告)号：US20060210588A1
公开(公告)日：2006-09-21
申请号：US10550580
申请日：2004-03-25
申请人： Martin Bachmann , Adrian Huber , Vania Manolova , Edwin Meijerink , Karl Proba , Alain Tissot
发明人： Martin Bachmann , Adrian Huber , Vania Manolova , Edwin Meijerink , Karl Proba , Alain Tissot
CPC分类号： A61K39/21 , A61K39/00 , A61K39/12 , A61K2039/5258 , A61K2039/55561 , C07K2319/40 , C12N7/00 , C12N2710/22023 , C12N2710/22042 , C12N2730/10122 , C12N2730/10123 , C12N2730/10142 , C12N2740/16034 , C12N2740/16222 , C12N2760/10022 , C12N2795/18122 , C12N2795/18123 , C12N2795/18142 , Y02A50/467
摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular HIV peptides linked thereto. Such CpG-VLPs are dramatically more immunogenic that their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against HIV peptides optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against HIV peptides are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
摘要翻译： 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含VLP的修饰病毒样颗粒（VLP），其可加载免疫刺激物质，特别是与含有非甲基化C和G（CpG）的DNA寡核苷酸以及与其连接的特定HIV肽。 这样的CpG-VLP显着地更具免疫原性，使其不含CpG的对应物并诱导增强的B和T细胞应答。 任何偶联，融合或附加到VLP的HIV肽的免疫应答相似地增强，因为针对HIV肽的免疫应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。
-
公开(公告)号：US20060222652A1
公开(公告)日：2006-10-05
申请号：US11270774
申请日：2005-11-10
申请人： Peter Sebbel , Nicolas Dunant , Martin Bachmann , Alain Tissot , Franziska Lechner , Wolfgang Renner , Frank Hennecke , Lars Nieba
发明人： Peter Sebbel , Nicolas Dunant , Martin Bachmann , Alain Tissot , Franziska Lechner , Wolfgang Renner , Frank Hennecke , Lars Nieba
IPC分类号： A61K39/40 , A61K39/295 , A61K39/29 , A61K39/108
CPC分类号： A61K39/385 , A61K38/00 , A61K2039/57 , A61K2039/6068 , A61K2039/625 , C07K14/245 , C07K2319/00 , Y10S530/807
摘要： The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.
-
公开(公告)号：US20070048287A1
公开(公告)日：2007-03-01
申请号：US11592127
申请日：2006-11-03
申请人： Wolfgang Renner , Martin Bachmann , Alain Tissot , Patrick Maurer , Franziska Lechner , Peter Sebbel , Christine Piossek
发明人： Wolfgang Renner , Martin Bachmann , Alain Tissot , Patrick Maurer , Franziska Lechner , Peter Sebbel , Christine Piossek
CPC分类号： A61K39/12 , A61K38/00 , A61K39/0005 , A61K39/0007 , A61K39/0008 , A61K39/001 , A61K39/35 , A61K39/385 , A61K39/39 , A61K47/6901 , A61K2039/5256 , A61K2039/5258 , A61K2039/6075 , A61K2039/627 , C07K14/005 , C07K14/523 , C07K14/5409 , C07K14/5437 , C07K16/00 , C07K16/082 , C07K16/22 , C07K16/2863 , C07K16/2875 , C07K16/40 , C07K16/4291 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2319/00 , C07K2319/30 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , C12N2795/18122 , C12N2795/18134 , Y02A50/412 , Y02A50/467
摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
-
公开(公告)号：US20100119540A1
公开(公告)日：2010-05-13
申请号：US12594650
申请日：2008-04-18
IPC分类号： A61K39/385
CPC分类号： A61K39/0013 , A61K47/646 , A61K47/6901 , A61K2039/5258 , A61K2039/55505
摘要： This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto.
摘要翻译： 本发明涉及疫苗接种和治疗或预防疾病领域。 特别地，本发明涉及通过在接种疫苗的受试者中诱导半抗原特异性抗体应答来治疗或预防疾病。 本发明还提供了通过在受试者中诱导半抗原特异性抗体来预防或治疗疾病的方法，所述方法包括向所述受试者施用包含RNA噬菌体的病毒样颗粒和至少一种与其连接的半抗原的组合物。
-
公开(公告)号：US20060204475A1
公开(公告)日：2006-09-14
申请号：US10551054
申请日：2004-03-25
申请人： Martin Bachmann , Vania Manolova , Edwin Meijerink , Karl Proba , Katrin Schwarz
发明人： Martin Bachmann , Vania Manolova , Edwin Meijerink , Karl Proba , Katrin Schwarz
CPC分类号： A61K39/39 , A61K2039/5258 , A61K2039/55561 , A61K2039/6075 , A61K2039/62 , A61K2039/64 , C07K14/005 , C07K14/4748 , C12N2710/22022 , C12N2730/10122 , C12N2730/10123 , C12N2760/10022 , Y02A50/467
摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpGVLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Thl type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
摘要翻译： 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含VLP的修饰病毒样颗粒（VLP），其可加载免疫刺激物质，特别是含有非甲基化C和G（CpG）的DNA寡核苷酸，以及衍生自与其连接的MelanA的特定肽。 这样的CpGVLP比其不含CpG的对应物显着地更具免疫原性，并且诱导增强的B和T细胞应答。 与VLP本身的免疫应答相似，对于任何偶联，融合或附着于VLP的MelanA肽类似物的免疫应答也相似地增强。 此外，针对MelanA肽类似物的T细胞应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。
-
公开(公告)号：US20060182793A1
公开(公告)日：2006-08-17
申请号：US10565264
申请日：2004-07-22
申请人： Martin Bachmann , Vania Manolova , Tazio Storni
发明人： Martin Bachmann , Vania Manolova , Tazio Storni
CPC分类号： A61K39/39 , A61K9/127 , A61K2039/55555 , A61K2039/55561 , Y02A50/412
摘要： Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFNα in vivo. These findings are relevant for the humans situation, since IFNα rather than IL-12 is the key cytokine for the induction of Th1 responses and anti-viral protection in humans.
摘要翻译： 已知脂质体可增强触发IL-12产生的K-（B-）型CpG的活性。 在本发明中，令人惊奇的发现是，脂质体还增强D-（A-）型CpG的活性，导致体内IFNα的产生。 这些发现与人类情况相关，因为IFNalpha而不是IL-12是人类Th1应答诱导和抗病毒保护的关键细胞因子。
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.047 秒)